Medina M, Wandosell F (2011) Deconstructing GSK-3: the fine regulation of its activity
Medicines regulator approves up to 7.2mg dose of semaglutide (Wegovy) for patients with obesity only [Internet]
Read more in ADA Meeting News: To view or add a comment, sign in More Relevant Posts At #EADVCongress 2025, were presenting new data from a phase 2a study evaluating our investigational therapy in #HidradenitisSuppurativa (HS) a chronic and debilitating inflammatory skin disease
The TRIUMPH phase 3 trials, initiated in August 2023, are evaluating retatrutide for obesity, T2D, NAFLD, knee osteoarthritis, and obstructive sleep apnea in larger, more diverse populations
Only a few drugs are approved to increase blood flow to the legs, and just one - cilostazol - is a top choice recommended by guidelines